(Q45905355)

English

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

scientific article published on 11 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Henk-Jan Guchelaar

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

F L Opdam

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

V O Dezentje

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

J den Hartigh

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A S Modak

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

R Vree

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

E Batman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C H Smorenburg

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

J W R Nortier

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

H Gelderblom

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

11 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

71

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

593-601

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

The pharmacology and clinical uses of tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Single time point diagnostic breath tests: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Orally administered endoxifen is a new therapeutic agent for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2034-4

21 January 2018

Identifiers

10.1007/S00280-012-2034-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228987%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45905355&oldid=2207440953"